CU20170097A7 - Anticuerpos anti-transtiretina - Google Patents

Anticuerpos anti-transtiretina

Info

Publication number
CU20170097A7
CU20170097A7 CUP2017000097A CU20170097A CU20170097A7 CU 20170097 A7 CU20170097 A7 CU 20170097A7 CU P2017000097 A CUP2017000097 A CU P2017000097A CU 20170097 A CU20170097 A CU 20170097A CU 20170097 A7 CU20170097 A7 CU 20170097A7
Authority
CU
Cuba
Prior art keywords
antibodies
ttr
transtiretine
accumulation
amyloidosis
Prior art date
Application number
CUP2017000097A
Other languages
English (en)
Other versions
CU24480B1 (es
Inventor
Avijit Chakrabartty
Jeffrey N Higaki
Yue Liu
Tarlochan S Nijjar
Original Assignee
Prothena Biosciences Ltd
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd, Univ Health Network filed Critical Prothena Biosciences Ltd
Publication of CU20170097A7 publication Critical patent/CU20170097A7/es
Publication of CU24480B1 publication Critical patent/CU24480B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>La invención proporciona anticuerpos que se unen específicamente la transtiretina (TTR). Los anticuerpos pueden usarse para tratar o efectuar la profilaxis de enfermedades o trastornos asociadas con acumulación de TTR o acumulación de depósitos de TTR (por ejemplo, amiloidosis TTE) . Los anticuerpos también pueden usarse para diagnosticar la amiloidosis TTR e inhibir o reducir la agregación de TTR, entre otras aplicaciones.<br />  </p>
CU2017000097A 2015-01-28 2016-01-28 Anticuerpos anti-transtiretina CU24480B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562109002P 2015-01-28 2015-01-28
US201562266556P 2015-12-11 2015-12-11
PCT/IB2016/050415 WO2016120810A1 (en) 2015-01-28 2016-01-28 Anti-transthyretin antibodies

Publications (2)

Publication Number Publication Date
CU20170097A7 true CU20170097A7 (es) 2018-03-13
CU24480B1 CU24480B1 (es) 2020-03-04

Family

ID=55299694

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000097A CU24480B1 (es) 2015-01-28 2016-01-28 Anticuerpos anti-transtiretina

Country Status (31)

Country Link
US (1) US20160251418A1 (es)
EP (2) EP3250592B1 (es)
JP (2) JP6748086B2 (es)
KR (2) KR102677203B1 (es)
CN (1) CN107406499B (es)
AU (1) AU2016210888C1 (es)
CA (1) CA2974912A1 (es)
CL (2) CL2017001924A1 (es)
CO (1) CO2017008476A2 (es)
CU (1) CU24480B1 (es)
DK (1) DK3250592T3 (es)
EA (1) EA036080B1 (es)
ES (1) ES2934656T3 (es)
FI (1) FI3250592T3 (es)
HR (1) HRP20221538T1 (es)
HU (1) HUE060878T2 (es)
IL (1) IL253633B (es)
LT (1) LT3250592T (es)
MX (1) MX394170B (es)
PE (1) PE20180217A1 (es)
PH (1) PH12017501318B1 (es)
PL (1) PL3250592T3 (es)
PT (1) PT3250592T (es)
RS (1) RS63906B1 (es)
SA (1) SA517382002B1 (es)
SG (2) SG10202101763VA (es)
SI (1) SI3250592T1 (es)
TW (2) TWI786505B (es)
UA (1) UA122142C2 (es)
WO (1) WO2016120810A1 (es)
ZA (1) ZA201705663B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
EP3478714A2 (en) * 2016-07-02 2019-05-08 Prothena Biosciences Limited Anti-transthyretin antibodies
SG11202002489YA (en) 2017-10-06 2020-04-29 Prothena Biosciences Ltd Anti-transthyretin antibodies
KR102581734B1 (ko) * 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
MA51223A (fr) 2017-11-29 2020-10-07 Prothena Biosciences Ltd Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine
EP3876713B1 (en) 2018-11-09 2024-10-02 Neurimmune AG Patient-derived amyloid xenograft rodent model
US20230035402A1 (en) 2020-03-18 2023-02-02 Al-S Pharma Ag Misfolded sod1 assay
WO2021228987A1 (en) 2020-05-12 2021-11-18 Neurimmune Ag Combination therapy for ttr amyloidosis
WO2021231982A1 (en) * 2020-05-14 2021-11-18 City Of Hope Smc1a antibodies and uses thereof
WO2022094152A1 (en) * 2020-10-28 2022-05-05 Neotope Neuroscience Limited Anti-transthyretin antibodies and methods of use thereof
CN113845593B (zh) * 2021-10-27 2023-03-10 福州迈新生物技术开发有限公司 抗α-SMA蛋白单克隆抗体、细胞系及其应用
WO2023086989A1 (en) * 2021-11-12 2023-05-19 Adrx, Inc. Transthyretin (ttr) monomer binding antibodies
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
US20240228637A9 (en) * 2022-10-19 2024-07-11 Ibio, Inc. Chemokine receptor 8 (ccr8) antibodies
TW202434624A (zh) 2022-11-15 2024-09-01 瑞士商紐立慕公司 治療或預防甲狀腺素運載蛋白調節之澱粉樣變性的方法
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
JP2026516527A (ja) 2023-05-19 2026-05-25 ニューリミューン アーゲー 筋骨格障害及び状態のための新規免疫療法
KR20260113091A (ko) 2023-11-15 2026-07-21 뉴리뮨 아게 항-트랜스티레틴 항체, 상기 항체를 포함하는 조성물 및 트랜스티레틴-매개 아밀로이드증의 치료 또는 예방 방법
CN122374011A (zh) 2023-12-15 2026-07-10 诺和诺德股份有限公司 稳定的液体制剂
WO2025238147A1 (en) 2024-05-15 2025-11-20 Neurimmune Ag Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies
WO2026030717A1 (en) * 2024-08-01 2026-02-05 Profluent Bio Inc. Systems and methods for protein design

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1470146B8 (en) 2001-12-28 2007-09-12 Amgen Fremont Inc. Antibodies against the muc18 antigen
DE50308030D1 (de) 2002-11-29 2007-10-04 Boehringer Ingelheim Pharma Neue neomycin-phosphotransferase-gene und verfahren zur selektion von hochproduzierenden rekombinanten zellen
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
EP1820022B1 (en) 2004-11-10 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
WO2007124345A2 (en) 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
PL2099823T5 (pl) 2006-12-01 2023-02-20 Seagen Inc. Wariant środków wiążących cel i jego zastosowania
EP2522730A1 (en) 2007-03-02 2012-11-14 Boehringer Ingelheim Pharma GmbH & Co. KG Improvement of protein production
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
FI20115165A0 (fi) * 2011-02-21 2011-02-21 Polysackaridforskning I Uppsala Ab Terapeuttisia ja diagnostisia menetelmiä
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
JP2016514091A (ja) 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
US20160168235A1 (en) * 2013-07-19 2016-06-16 Board Of Regents Of The University Of Texas System Transthyretin amyloid-selective and polyreactive catabodies
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법

Also Published As

Publication number Publication date
JP2018506277A (ja) 2018-03-08
HRP20221538T1 (hr) 2023-03-03
ZA201705663B (en) 2018-08-29
TWI786505B (zh) 2022-12-11
JP7028923B2 (ja) 2022-03-02
PH12017501318A1 (en) 2018-02-05
PE20180217A1 (es) 2018-01-31
CL2017001924A1 (es) 2018-04-27
RS63906B1 (sr) 2023-02-28
EP4134379A1 (en) 2023-02-15
PL3250592T3 (pl) 2023-06-19
ES2934656T3 (es) 2023-02-23
TW202124436A (zh) 2021-07-01
KR20230156164A (ko) 2023-11-13
PT3250592T (pt) 2022-12-28
WO2016120810A1 (en) 2016-08-04
NZ733896A (en) 2024-11-29
BR112017016330A2 (en) 2018-04-03
CO2017008476A2 (es) 2018-01-16
DK3250592T3 (en) 2023-01-09
JP2020185009A (ja) 2020-11-19
PH12017501318B1 (en) 2018-02-05
MX394170B (es) 2025-03-24
CN107406499A (zh) 2017-11-28
HUE060878T2 (hu) 2023-04-28
CA2974912A1 (en) 2016-08-04
EP3250592B1 (en) 2022-10-05
MX2017009806A (es) 2018-08-15
SI3250592T1 (sl) 2023-03-31
UA122142C2 (uk) 2020-09-25
CL2022003027A1 (es) 2023-06-09
IL253633B (en) 2021-06-30
JP6748086B2 (ja) 2020-09-02
EA201791712A1 (ru) 2017-12-29
LT3250592T (lt) 2023-02-10
US20160251418A1 (en) 2016-09-01
AU2016210888A1 (en) 2017-08-10
CU24480B1 (es) 2020-03-04
EA036080B1 (ru) 2020-09-23
SA517382002B1 (ar) 2021-11-25
TW201632554A (zh) 2016-09-16
CN107406499B (zh) 2021-10-22
FI3250592T3 (fi) 2023-01-13
EP3250592A1 (en) 2017-12-06
IL253633A0 (en) 2017-09-28
KR20170106469A (ko) 2017-09-20
AU2016210888B2 (en) 2021-11-04
AU2016210888C1 (en) 2022-06-02
SG11201706124VA (en) 2017-08-30
KR102598180B1 (ko) 2023-11-03
SG10202101763VA (en) 2021-04-29
KR102677203B1 (ko) 2024-06-20
TWI718122B (zh) 2021-02-11

Similar Documents

Publication Publication Date Title
CO2017008476A2 (es) Anticuerpos anti-transtiretina
CO2017008482A2 (es) Anticuerpos anti-transtiretina
CU20200021A7 (es) Anticuerpos anti-transtiretina
CU20170096A7 (es) Anticuerpos anti-transtiretina
CU20170052A7 (es) Moléculas de anticuerpo que se unen a pd-l1
CL2017002401A1 (es) Anticuerpos contra icos
CU24481B1 (es) Moléculas de anticuerpo que se unen a lag-3
CU24427B1 (es) Moléculas de anticuerpo que se unen a tim-3
MX2018006385A (es) Moleculas de anticuerpo contra april y usos de las mismas.
CR20170095A (es) Anticuerpos anti-cll-1 e inmunoconjugados referencias recíprocas con solicitudes relacionadas
AR103549A1 (es) Anticuerpos anti-transtiretina
AR113345A1 (es) Anticuerpos anti-transtiretina
EA202090891A1 (ru) Молекулы антител против cd138 и их применение
AR103548A1 (es) Anticuerpos anti-transtiretina
EA202090898A1 (ru) Антитранстиретиновые антитела
HK1240249A1 (en) Anti-transthyretin antibodies